Download PDF
Nervenheilkunde 2003; 22(10): 520-524
DOI: 10.1055/s-0038-1626345
Original- und Übersichtsarbeiten/Original and Review Articles
Schattauer GmbH

Wann ist Gabapentin zur Behandlung von Epilepsien vorteilhafter als Carbamazepin?

In which cases is gabapentin more advantageous than carbamazepine in the treatment of epilepsy?
D. Schmidt
1   Arbeitsgruppe Epilepsieforschung Berlin
,
C. E. Elger
2   Klinik und Poliklinik für Epileptologie, Universität Bonn
,
B. J. Steinhoff
3   Epilepsiezentrum Kork
,
H. Stefan
4   Zentrum Epilepsie – Neurologische Klinik und Poliklinik der Universität Erlangen-Nürnberg
› Author Affiliations
Further Information

Publication History

Publication Date:
15 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Nach inzwischen langjährigem Einsatz von Gabapentin in der praktischen Epilepsiebehandlung lassen sich die positiven Erfahrungen wie folgt zusammenfassen: Wirksamkeit in Mono-und Kombinationstherapie, sehr gute Verträglichkeit ohne Exanthem-Risiko, leichte Steuerbarkeit ohne Notwendigkeit einer langwierigen Eindosierung und kein klinisch relevantes Interaktionsrisiko bei medikationspflichtiger Multimorbidität, da Gabapentin weder enzymhemmend noch -induzierend ist. Gegenüber älteren Präparaten wie Carbamazepin bietet Gabapentin erhebliche Vorteile in der Langzeit-Verträglichkeit, sodass es speziell bei älteren und nebenwirkungsempfindlichen Patienten mit fokalen Anfällen nach Abwägung der individuellen Gegebenheiten bevorzugt eingesetzt werden sollte.

Summary

During many years of clinical use gabapentin has been shown to have the following benefits: Efficacy in monoand combination therapy, very good tolerability without risk of rashes, and easy handling without the need for slow titration. Furthermore, gabapentin has a low interaction risk when it is given in combination therapy or with other medication in patients with multimorbidity, since it is neither an enzyme inducer nor an inhibitor. Compared to old drugs such as carbamazepine, gabapentin offers significant advantages in long-term tolerability. As a consequence, after careful consideration of all relevant factors, gabapentin should be preferred particularly in the elderly and those prone to suffer from adverse effects of other AEDs.

Schlüsselwörter

Gabapentin - Epilepsie - Epilepsietherapie - Antiepileptika - Antikonvulsiva

Keywords

Gabapentin - epilepsy - epilepsy treatment - antiepileptic drugs - anticonvulsants
 

  • Literatur

  • 1 Bowley C, Kerr M. Epilepsy and intellectual disability. J Intellect Disabil Res 2000; 44: 65-75.
    Google Scholar
  • 2 Brodie MJ. et al. Gabapentin versus Lamotrigine monotherapy: a double-blind comparison. Epilepsia 2002; 43 (09) 993-1000.
    CrossrefPubMedGoogle Scholar
  • 3 Chadwick DW. et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology 1998; 51: 1282-8.
    CrossrefPubMedGoogle Scholar
  • 4 Crawford P, Brown S, Kerr M. et al. A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. Seizure 2001; 10: 107-15.
    CrossrefPubMedGoogle Scholar
  • 5 DeToledo JC. et al. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997; 19: 394-6.
    CrossrefPubMedGoogle Scholar
  • 6 Deutsche Gesellschaft für Neurologie. Leitlinien: Epilepsien im Erwachsenenalter. 2002 http://www.dgn.org/leitl.html.
    PubMedGoogle Scholar
  • 7 Elger CE, Schmidt D. Aktuelle Epilepsietherapie: kurzgefasst. München: Zuckschwerdt; 2003.
    Google Scholar
  • 8 Farhat G, Yamout B, Mikati MA. et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002; 58: 1348-53.
    CrossrefPubMedGoogle Scholar
  • 9 Gillberg C, Soderstrom H. Learning disability. Lancet 2003; 362: 811-21.
    CrossrefPubMedGoogle Scholar
  • 10 Khurana DS. et al. Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr 1996; 128: 829-33.
    CrossrefPubMedGoogle Scholar
  • 11 Leach JP. et al. Gabapentin and cognition: a double-blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiat 1997; 62: 372-6.
    CrossrefPubMedGoogle Scholar
  • 12 Martin R. et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999; 52 (02) 321-7.
    CrossrefPubMedGoogle Scholar
  • 13 Meador KJ, Loring DW, Ray PG. et al. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 1999; 40: 1279-85.
    CrossrefPubMedGoogle Scholar
  • 14 Mikati MA, Choueri R, Khurana DS. et al. Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. J Intellect Disabil Res 1998; 42 (Suppl. 01) 57-62.
    PubMedGoogle Scholar
  • 15 Morrell M. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 2003; 44 (Suppl. 04) 11-20.
    PubMedGoogle Scholar
  • 16 Pack AM, Morrell M. Adverse effects of antiepileptic drugs on bone structure. CNS Drugs 2001; 15 (08) 633-42.
    CrossrefPubMedGoogle Scholar
  • 17 Pellock JM, Morton JD. Treatment of epilepsy in the multiple handicapped. Ment Retard Dev Disabil Res Rev 2000; 06: 309-23.
    CrossrefPubMedGoogle Scholar
  • 18 Platt D. Altersmedizin. Stuttgart: Schattauer-Verlag; 1997.
    Google Scholar
  • 19 Schmidt D, Elger CE. Praktische Epilepsiebehandlung, 2. Auflage. Stuttgart: Thieme; 2002.
    Google Scholar
  • 20 Schmidt D, Elger CE, Brandl U. et al. Empfehlungen zur Behandlung fokaler Epilepsien mit Gabapentin – ein Konsens. Nervenheilkunde 2001; 20: 580-5.
    Google Scholar
  • 21 Schmidt D, Stefan H, Elger CE. Praktische Erfahrungen mit der Gabapentin-Monotherapie. Nervenheilkunde 2001; 20: 321-5.
    Google Scholar
  • 22 Stefan H. Epilepsien: Diagnose und Behandlung, 3. Auflage. Stuttgart: Thieme; 1999.
    Google Scholar
  • 23 Stefani A, Spadoni F, Giacomini P. et al. The effects of gabapentin on different ligand-and voltage-gated currents in isolated cortical neurons. Epilepsy Research 2001; 43: 239-48.
    CrossrefPubMedGoogle Scholar
  • 24 Steffenburg S, Gillberg C, Steffenburg U. Psychiatric disorders in children and adolescents with mental retardation and active epilepsy. Arch Neurol 1996; 53: 904-12.
    CrossrefPubMedGoogle Scholar
  • 25 Strolin-Benedetti M. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundamental and Clinical Pharmacology 2000; 14 (04) 301-9.
    CrossrefPubMedGoogle Scholar